Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Edgewise Therapeutics ( (EWTX) ) has provided an announcement.
On June 26, 2025, Edgewise Therapeutics announced positive results from its sevasemten program targeting Becker and Duchenne muscular dystrophies. This development could significantly impact the company’s operations and industry positioning by advancing treatment options for these rare muscle disorders.
The most recent analyst rating on (EWTX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Edgewise Therapeutics stock, see the EWTX Stock Forecast page.
Spark’s Take on EWTX Stock
According to Spark, TipRanks’ AI Analyst, EWTX is a Underperform.
Edgewise Therapeutics’ overall score reflects significant risks due to its pre-revenue stage and increasing losses. Positive corporate events, including substantial fundraising and promising trial results, offer growth potential. However, the bearish technical indicators and valuation challenges highlight the stock’s high-risk profile typical of early-stage biotech companies.
To see Spark’s full report on EWTX stock, click here.
More about Edgewise Therapeutics
Edgewise Therapeutics operates in the biopharmaceutical industry, focusing on developing therapies for rare muscle disorders such as Becker and Duchenne muscular dystrophies.
Average Trading Volume: 1,597,678
Technical Sentiment Signal: Sell
Current Market Cap: $1.51B
For an in-depth examination of EWTX stock, go to TipRanks’ Overview page.